Dr. Eric B. Suhler, MD
Ophthalmology (Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 90
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of Texas Southwestern Medical School at Dallas
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician primary
OR license MD23983 -
Ophthalmology Physician
OR license MD23983
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohsu Hospital and Clinics Portland, OR
Medical groups
- University Professional Services (1,724 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 90
- Services billed
- 487
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 130 | 65 |
| Imaging of retina | 99 | 62 |
| Established patient office or other outpatient visit, 20-29 minutes | 28 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Portland, OR | 31 |
| Prednisone Other prescribers in Portland, OR | 20 |
| Mycophenolate Mofetil Other prescribers in Portland, OR | 16 |
| Difluprednate | 12 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Portland, OR | 11 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Portland, OR | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 7 payments worth $8,841 in total to this clinician.
| F. Hoffmann-la Roche AG | $6,075 |
|---|---|
| Regeneron Pharmaceuticals, Inc. | $2,577 |
| Genentech, Inc. | $189 |
| Consulting Fee | $8,652 |
|---|---|
| Food and Beverage | $189 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| F. Hoffmann-la Roche AG Oct 14, 2025 | Consulting Fee | $2,363 |
| Regeneron Pharmaceuticals, Inc. Jun 13, 2025 | Consulting Fee | $1,718 |
| F. Hoffmann-la Roche AG Mar 24, 2025 | Consulting Fee | $1,688 |
| F. Hoffmann-la Roche AG Jul 2, 2025 | Consulting Fee | $1,350 |
| Regeneron Pharmaceuticals, Inc. Jun 13, 2025 | Consulting Fee | $859 |
| F. Hoffmann-la Roche AG Apr 1, 2025 | Consulting Fee | $675 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $23,244 in research payments for these studies, mostly to the institutions running them.
- A phase iii study to investigate RO7200220 in patients with uveitic macular edema
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.